Close Menu

NEW YORK (GenomeWeb News) – Waters today reported that its revenues in the second quarter were up 7 percent, driven by broad-based pharmaceutical demand and strong US sales.

The company posted Q2 revenues of $481.8 million, up from $451.1 million in Q2 2013 and beating the average Wall Street estimate of $476.1 million.

It reported a profit of $96.5 million, or $1.13 per share, during the quarter, compared to a profit of $89.3 million, or $1.03 per share, a year ago. On a non-GAAP basis, Waters had EPS of $1.22, beating the average analyst estimate of $1.21.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that visa costs could prevent scientists and others from coming to the UK.

The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.

Nature News says some preprint repositories may close down due to a lack of funds to cover costs.

In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.